Cargando…

Defining the relationship between Plasmodium vivax parasite rate and clinical disease

BACKGROUND: Though essential to the development and evaluation of national malaria control programmes, precise enumeration of the clinical illness burden of malaria in endemic countries remains challenging where local surveillance systems are incomplete. Strategies to infer annual incidence rates fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Battle, Katherine E, Cameron, Ewan, Guerra, Carlos A, Golding, Nick, Duda, Kirsten A, Howes, Rosalind E, Elyazar, Iqbal RF, Price, Ric N, Baird, J Kevin, Reiner, Robert C, Smith, David L, Gething, Peter W, Hay, Simon I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429942/
https://www.ncbi.nlm.nih.gov/pubmed/25948111
http://dx.doi.org/10.1186/s12936-015-0706-3
_version_ 1782371102791565312
author Battle, Katherine E
Cameron, Ewan
Guerra, Carlos A
Golding, Nick
Duda, Kirsten A
Howes, Rosalind E
Elyazar, Iqbal RF
Price, Ric N
Baird, J Kevin
Reiner, Robert C
Smith, David L
Gething, Peter W
Hay, Simon I
author_facet Battle, Katherine E
Cameron, Ewan
Guerra, Carlos A
Golding, Nick
Duda, Kirsten A
Howes, Rosalind E
Elyazar, Iqbal RF
Price, Ric N
Baird, J Kevin
Reiner, Robert C
Smith, David L
Gething, Peter W
Hay, Simon I
author_sort Battle, Katherine E
collection PubMed
description BACKGROUND: Though essential to the development and evaluation of national malaria control programmes, precise enumeration of the clinical illness burden of malaria in endemic countries remains challenging where local surveillance systems are incomplete. Strategies to infer annual incidence rates from parasite prevalence survey compilations have proven effective in the specific case of Plasmodium falciparum, but have yet to be developed for Plasmodium vivax. Moreover, defining the relationship between P. vivax prevalence and clinical incidence may also allow levels of endemicity to be inferred for areas where the information balance is reversed, that is, incident case numbers are more widely gathered than parasite surveys; both applications ultimately facilitating cartographic estimates of P. vivax transmission intensity and its ensuring disease burden. METHODS: A search for active case detection surveys was conducted and the recorded incidence values were matched to local, contemporary parasite rate measures and classified to geographic zones of differing relapse phenotypes. A hierarchical Bayesian model was fitted to these data to quantify the relationship between prevalence and incidence while accounting for variation among relapse zones. RESULTS: The model, fitted with 176 concurrently measured P. vivax incidence and prevalence records, was a linear regression of the logarithm of incidence against the logarithm of age-standardized prevalence. Specific relationships for the six relapse zones where data were available were drawn, as well as a pooled overall relationship. The slope of the curves varied among relapse zones; zones with short predicted time to relapse had steeper slopes than those observed to contain long-latency relapse phenotypes. CONCLUSIONS: The fitted relationships, along with appropriate uncertainty metrics, allow for estimates of clinical incidence of known confidence to be made from wherever P. vivax prevalence data are available. This is a prerequisite for cartographic-based inferences about the global burden of morbidity due to P. vivax, which will be used to inform control efforts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0706-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4429942
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44299422015-05-14 Defining the relationship between Plasmodium vivax parasite rate and clinical disease Battle, Katherine E Cameron, Ewan Guerra, Carlos A Golding, Nick Duda, Kirsten A Howes, Rosalind E Elyazar, Iqbal RF Price, Ric N Baird, J Kevin Reiner, Robert C Smith, David L Gething, Peter W Hay, Simon I Malar J Research BACKGROUND: Though essential to the development and evaluation of national malaria control programmes, precise enumeration of the clinical illness burden of malaria in endemic countries remains challenging where local surveillance systems are incomplete. Strategies to infer annual incidence rates from parasite prevalence survey compilations have proven effective in the specific case of Plasmodium falciparum, but have yet to be developed for Plasmodium vivax. Moreover, defining the relationship between P. vivax prevalence and clinical incidence may also allow levels of endemicity to be inferred for areas where the information balance is reversed, that is, incident case numbers are more widely gathered than parasite surveys; both applications ultimately facilitating cartographic estimates of P. vivax transmission intensity and its ensuring disease burden. METHODS: A search for active case detection surveys was conducted and the recorded incidence values were matched to local, contemporary parasite rate measures and classified to geographic zones of differing relapse phenotypes. A hierarchical Bayesian model was fitted to these data to quantify the relationship between prevalence and incidence while accounting for variation among relapse zones. RESULTS: The model, fitted with 176 concurrently measured P. vivax incidence and prevalence records, was a linear regression of the logarithm of incidence against the logarithm of age-standardized prevalence. Specific relationships for the six relapse zones where data were available were drawn, as well as a pooled overall relationship. The slope of the curves varied among relapse zones; zones with short predicted time to relapse had steeper slopes than those observed to contain long-latency relapse phenotypes. CONCLUSIONS: The fitted relationships, along with appropriate uncertainty metrics, allow for estimates of clinical incidence of known confidence to be made from wherever P. vivax prevalence data are available. This is a prerequisite for cartographic-based inferences about the global burden of morbidity due to P. vivax, which will be used to inform control efforts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0706-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-07 /pmc/articles/PMC4429942/ /pubmed/25948111 http://dx.doi.org/10.1186/s12936-015-0706-3 Text en © Battle et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Battle, Katherine E
Cameron, Ewan
Guerra, Carlos A
Golding, Nick
Duda, Kirsten A
Howes, Rosalind E
Elyazar, Iqbal RF
Price, Ric N
Baird, J Kevin
Reiner, Robert C
Smith, David L
Gething, Peter W
Hay, Simon I
Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title_full Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title_fullStr Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title_full_unstemmed Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title_short Defining the relationship between Plasmodium vivax parasite rate and clinical disease
title_sort defining the relationship between plasmodium vivax parasite rate and clinical disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429942/
https://www.ncbi.nlm.nih.gov/pubmed/25948111
http://dx.doi.org/10.1186/s12936-015-0706-3
work_keys_str_mv AT battlekatherinee definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT cameronewan definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT guerracarlosa definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT goldingnick definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT dudakirstena definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT howesrosalinde definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT elyazariqbalrf definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT pricericn definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT bairdjkevin definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT reinerrobertc definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT smithdavidl definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT gethingpeterw definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
AT haysimoni definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease